You are here

Share:

Search Technologies

Showing 1-20 of 50 results found

Metastatic ovarian cancer mouse models and cell lines for preclinical studies

NCI's Center for Advanced Preclinical Research (CAPR) has developed a Serous Epithelial Ovarian Cancer (SEOC) genetically engineered mouse model (GEM), GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom, with several key histopathologic, immunophenotypical, and genetic features of human SEOC. NCI CAPR seeks licensees for this technology.

A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences

Recent research has demonstrated that neoantigen-specific T-cell receptors (TCRs) can be isolated from a cancer patient’s lymphocytes. These TCRs may be used to engineer populations of tumor-reactive T cells for cancer immunotherapies. Obtaining sequences of these functional TCRs is a critical initial step in preparing this type of personalized cancer treatment; however, current methods are time-consuming and labor-intensive. Scientists at the National Cancer Institute (NCI) have developed a rapid and robust method of isolating the sequences of mutation-specific TCRs to alleviate these issues; they seek licensing and/or co-development research collaborations for the development of a method for isolating the sequences of tumor-reactive TCRs. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at sar@nih.gov.

Murine metastatic pancreatic adenocarcinoma cell lines

Researchers at the National Cancer Institute (NCI) developed orthotopic allograft models for pancreatic cancer that utilize cells or tumor fragments implanted into the cancer-free pancreata of recipient immunocompetent mice. NCI seeks licensees to commercialize this invention.

A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof

Researchers at the National Cancer Institute (NCI) have developed an improved class of heptamethine cyanine fluorophore dyes useful for imaging applications in the near-IR range (750-850 nm). A new chemical reaction has been developed that provides easy access to novel molecules with improved properties. Specifically, the dyes display greater resistance to thiol nucleophiles, and are more robust while maintaining excellent optical properties. The dyes have been successfully employed in various in vivo imaging applications and in vitro labeling and microscopy applications. The NCI seek co-development or licensees to develop them as targetable agents for optical-guided surgical interventions.

Optical Microscope Software for Breast Cancer Diagnosis

Researchers from NCI and Rudgers University developed  methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell. The National Cancer Institute seeks parties interested in collaborative research to co-develop diagnostic methods for detection of cancer using spatial genome organization.

Mouse Xenograft Model for Mesothelioma

The National Cancer Institute is seeking parties interested in collaborative research to co-develop, evaluate, or commercialize a new mouse model for monoclonal antibodies and immunoconjugates that target malignant mesotheliomas. Applications of the technology include models for screening compounds as potential therapeutics for mesothelioma and for studying the pathology of mesothelioma.

Novel Fusion Proteins for HIV Vaccine

The National Cancer Institute’s Cancer and Inflammation Program seeks parties to license gp120 and CD4-induced antibody fusion proteins for use in an HIV vaccine.

Method and Device for Selectively Labeling RNA

The National Cancer Institute's Structure Biophysics Lab seeks partners interested in licensing or co-developing a technology to site-specifically label RNA.

Target for Anti-Tumor Immune Responses

The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy.

Knockout and Conditional Knockout Mice-GPR116

Pulmonary surfactant plays a critical role in preventing alveolar collapse by decreasing surface tension at the alveolar air-liquid interface. Surfactant deficiency contributes to the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), common disorders that can afflict patients of all ages and carry a mortality rate greater than 25%. Excess surfactant leads to pulmonary alveolar proteinosis. NCI investigators created a G-protein coupled receptor GPR116 mutant mouse model and showed that GPR116 plays a previously unexpected, essential role in maintaining normal surfactant levels in the lung. The National Cancer Institute seeks partners interested in collaborative research to license surfactant modulating agents for the treatment of surfactant related lung disorders.

Methods of Producing Effective T-cell Populations Using Akt Inhibitors

Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.

Device for Growing Mammalian Cells on EM Grids

A device used to hold transmission electron microscopy grids that allows adherent mammalian cells to grow on and the 3D printing software to create the device, which the NCI seeks to license.

BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research

The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.

Pages